1
|
Velez R, Domenech E, Rodríguez-Cortés A, Barrios D, Tebar S, Fernández-Arévalo A, Aguilar R, Dobaño C, Alberola J, Cairó J, Gállego M. Evaluation of canine leishmaniosis vaccine CaniLeish® under field conditions in native dog populations from an endemic Mediterranean area-A randomized controlled trial. Acta Trop 2020; 205:105387. [PMID: 32035053 DOI: 10.1016/j.actatropica.2020.105387] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2019] [Revised: 02/04/2020] [Accepted: 02/04/2020] [Indexed: 12/26/2022]
Abstract
Dog vaccination is considered an effective way of reducing Leishmania infantum infection incidence in the canine population, as well as its transmission to humans. However, the use of partially effective vaccines can have the detrimental effect of "masking" vaccinated asymptomatic carriers, capable of harbouring the parasite and transmitting it to naïve individuals. After eight years on the European market, few studies have been released on CaniLeish® vaccine safety and efficacy. The present study, a one-year randomized CaniLeish® vaccine field trial, was performed in a canine leishmaniosis endemic area and included animals selected from a native dog population (n = 168). No severe adverse reactions were observed in vaccinated dogs (n = 85). Cases of active L. infantum infection were detected by serological, molecular and clinical follow-up of dogs. One-year post-vaccination, no differences in number or severity of L. infantum active infections were observed between study groups (n = 4 in each group). Vaccine-induced cellular immunity, assessed through interferon-γ quantification, showed significantly higher levels of this cytokine one-month post-vaccination in the vaccine group (p < 0.001), but no differences were observed after nine months between trial groups (p = 0.078). These results fail to support the reported CaniLeish® efficacy in the prevention of active L. infantum infection in dogs from endemic areas and naturally exposed to the parasite.
Collapse
Affiliation(s)
- R Velez
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
| | - E Domenech
- Hospital Veterinari Canis, Girona, Spain
| | - A Rodríguez-Cortés
- Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain.
| | - D Barrios
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
| | - S Tebar
- Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
| | - A Fernández-Arévalo
- Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain; Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - R Aguilar
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
| | - C Dobaño
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain.
| | - J Alberola
- Departament de Farmacologia, de Terapèutica i de Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain.
| | - J Cairó
- Hospital Veterinari Canis, Girona, Spain.
| | - M Gállego
- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain; Secció de Parasitologia, Departament de Biologia, Sanitat i Medi Ambient, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Barcelona, Spain.
| |
Collapse
|
2
|
Moraes-Souza RQ, Reinaque AP, Soares TS, Silva ALT, Giunchetti RC, Takano MAS, Akamatsu MA, Kubrusly FS, Lúcio-Macarini F, Raw I, Iourtov D, Ho PL, Bueno LL, Fujiwara RT, Volpato GT. Safety evaluation of a vaccine: Effect in maternal reproductive outcome and fetal anomaly frequency in rats using a leishmanial vaccine as a model. PLoS One 2017; 12:e0172525. [PMID: 28249007 PMCID: PMC5332059 DOI: 10.1371/journal.pone.0172525] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2016] [Accepted: 02/06/2017] [Indexed: 02/08/2023] Open
Abstract
While the immunogenic potential of the vaccination against infectious diseases was extensively shown, data on the safety assessment of recombinant proteins in vaccine formulations administered during pregnancy are still scarce. In the current study, the antigenicity of a vaccine against leishmaniasis (based on Leishmania braziliensis recombinant protein peroxidoxin) during pregnancy and possible maternal reproductive outcomes and fetal anomalies after immunization with a leishmanial vaccine or adjuvant alone (Bordetella pertussis derived MPLA adjuvant) were assessed. Rats were mated and allocated in three groups: Control—rats received saline; Adjuvant—rats received the adjuvant MPLA, and Vaccine—rats received the combination of MPLA and peroxidoxin. The administration was subcutaneously at the dorsal region, three times (days 0, 7, 14 of pregnancy). On day 21 of pregnancy, all rats were bled for biochemical and immunological measurements. The gravid uterus was weighed with its contents, and the fetuses were analyzed. The immunization with peroxidoxin induced a significant production of circulating IgG levels compared to other groups but caused a significant in post-implantation loss (14.7%) when compared to Control (5.0%) and Adjuvant (4.4%) groups. Furthermore, a significantly high rate of fetal visceral anomalies, such as hydronephrosis and convoluted ureter, was also observed in animals that received vaccine when compared to Control or Adjuvant groups. These data indicate the importance of safety evaluation of vaccines during pregnancy and the limited use of peroxidoxin administration during pregnancy. More importantly, the safety monitoring of immunization with MPLA derived from Bordetella pertussis demonstrated no reproductive outcomes associated with adjuvant administration, suggesting its safe use during pregnancy.
Collapse
Affiliation(s)
- Rafaianne Q. Moraes-Souza
- Laboratory of System Physiology and Reproductive Toxicology, Institute of Biological and Health Sciences, Federal University of Mato Grosso (UFMT) - Barra do Garças, Mato Grosso State, Brazil
| | - Ana Paula Reinaque
- Laboratory of Immunology and Genomics of Parasites, Department of Parasitology, Biological Sciences Institute, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Gerais State, Brazil
| | - Thaigra S. Soares
- Laboratory of System Physiology and Reproductive Toxicology, Institute of Biological and Health Sciences, Federal University of Mato Grosso (UFMT) - Barra do Garças, Mato Grosso State, Brazil
| | - Ana Luiza T. Silva
- Laboratory of Immunology and Genomics of Parasites, Department of Parasitology, Biological Sciences Institute, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Gerais State, Brazil
| | - Rodolfo C. Giunchetti
- Laboratory of Cell-Cell Interactions, Morphology Department, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
| | - Maria A. S. Takano
- Division of Technological Development and Production (DDTP), Butantan Institute, São Paulo, Brazil
| | - Milena A. Akamatsu
- Division of Technological Development and Production (DDTP), Butantan Institute, São Paulo, Brazil
| | - Flávia S. Kubrusly
- Division of Technological Development and Production (DDTP), Butantan Institute, São Paulo, Brazil
| | - Fernanda Lúcio-Macarini
- Division of Technological Development and Production (DDTP), Butantan Institute, São Paulo, Brazil
| | - Isaias Raw
- Division of Technological Development and Production (DDTP), Butantan Institute, São Paulo, Brazil
| | - Dmitri Iourtov
- Division of Technological Development and Production (DDTP), Butantan Institute, São Paulo, Brazil
| | - Paulo Lee Ho
- Division of Technological Development and Production (DDTP), Butantan Institute, São Paulo, Brazil
| | - Lilian L. Bueno
- Laboratory of Immunology and Genomics of Parasites, Department of Parasitology, Biological Sciences Institute, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Gerais State, Brazil
| | - Ricardo T. Fujiwara
- Laboratory of Immunology and Genomics of Parasites, Department of Parasitology, Biological Sciences Institute, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Gerais State, Brazil
| | - Gustavo T. Volpato
- Laboratory of System Physiology and Reproductive Toxicology, Institute of Biological and Health Sciences, Federal University of Mato Grosso (UFMT) - Barra do Garças, Mato Grosso State, Brazil
- * E-mail:
| |
Collapse
|
3
|
Carson C, Antoniou M, Ruiz-Argüello MB, Alcami A, Christodoulou V, Messaritakis I, Blackwell JM, Courtenay O. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine 2009; 27:1080-6. [PMID: 19095029 PMCID: PMC2663027 DOI: 10.1016/j.vaccine.2008.11.094] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2008] [Revised: 11/19/2008] [Accepted: 11/27/2008] [Indexed: 01/28/2023]
Abstract
Previous studies demonstrated safety, immunogenicity and efficacy of DNA/modified vaccinia virus Ankara (MVA) prime/boost vaccines expressing tryparedoxin peroxidase (TRYP) and Leishmania homologue of the mammalian receptor for activated C kinase (LACK) against Leishmania major challenge in mice, which was consistent with results from TRYP protein/adjuvant combinations in non-human primates. This study aimed to conduct safety and immunogenicity trials of these DNA/MVA vaccines in dogs, the natural reservoir host of Leishmania infantum, followed-up for 4 months post-vaccination. In a cohort of 22 uninfected outbred dogs, blinded randomised administration of 1000 microg (high dose) or 100 microg (low dose) DNA prime (day 0) and 1x10(8)pfu MVA boost (day 28) was shown to be safe and showed no clinical side effects. High dose DNA/MVA vaccinated TRYP dogs produced statistically higher mean levels of the type-1 pro-inflammatory cytokine IFN-gamma than controls in whole blood assays (WBA) stimulated with the recombinant vaccine antigen TRYP, up to the final sampling at day 126, and in the absence of challenge with Leishmania. TRYP vaccinated dogs also demonstrated significantly higher TRYP-specific total IgG and IgG2 subtype titres than in controls, and positive in vivo intradermal reactions at day 156 in the absence of natural infection, observed in 6/8 TRYP vaccinated dogs. No significant increases in IFN-gamma in LACK-stimulated WBA, or in LACK-specific IgG levels, were detected in LACK vaccinated dogs compared to controls, and only 2/9 LACK vaccinated dogs demonstrated DTH responses at day 156. In all groups, IgG1 subclass responses and antigen-specific stimulation of IL-10 were similar to controls demonstrating an absence of Th2/T(reg) response, as expected in the absence of in vivo restimulation or natural/experimental challenge with Leishmania. These collective results indicate significant antigen-specific type-1 responses and in vivo memory phase cellular immune responses, consistent with superior potential for protective vaccine immunogenicity of DNA/MVA TRYP over LACK.
Collapse
MESH Headings
- Animals
- Antibodies, Protozoan/blood
- Antigens, Protozoan/genetics
- Antigens, Protozoan/immunology
- Dogs
- Immunization, Secondary/methods
- Immunoglobulin G/blood
- Interferon-gamma/metabolism
- Leishmania infantum/immunology
- Leishmaniasis Vaccines/administration & dosage
- Leishmaniasis Vaccines/adverse effects
- Leishmaniasis Vaccines/immunology
- Leishmaniasis, Visceral/immunology
- Leishmaniasis, Visceral/prevention & control
- Leukocytes, Mononuclear/immunology
- Peroxidases/genetics
- Peroxidases/immunology
- Protozoan Proteins/genetics
- Protozoan Proteins/immunology
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/adverse effects
- Vaccines, DNA/immunology
- Vaccinia virus/genetics
Collapse
Affiliation(s)
- Connor Carson
- Populations and Disease Research Group, Department of Biological Sciences, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK.
| | | | | | | | | | | | | | | |
Collapse
|